AbbVie Shares Outstanding 2010-2024 | ABBV

AbbVie shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • AbbVie shares outstanding for the quarter ending March 31, 2024 were 1.773B, a 0.17% decline year-over-year.
  • AbbVie 2023 shares outstanding were 1.773B, a 0.28% decline from 2022.
  • AbbVie 2022 shares outstanding were 1.778B, a 0.06% increase from 2021.
  • AbbVie 2021 shares outstanding were 1.777B, a 6.22% increase from 2020.
AbbVie Annual Shares Outstanding
(Millions of Shares)
2023 1,773
2022 1,778
2021 1,777
2020 1,673
2019 1,484
2018 1,546
2017 1,603
2016 1,631
2015 1,637
2014 1,610
2013 1,604
2012 1,577
2011 1,577
2010 1,577
2009
AbbVie Quarterly Shares Outstanding
(Millions of Shares)
2024-03-31 1,773
2023-12-31 1,773
2023-09-30 1,771
2023-06-30 1,771
2023-03-31 1,776
2022-12-31 1,778
2022-09-30 1,776
2022-06-30 1,776
2022-03-31 1,778
2021-12-31 1,777
2021-09-30 1,777
2021-06-30 1,776
2021-03-31 1,775
2020-12-31 1,673
2020-09-30 1,774
2020-06-30 1,647
2020-03-31 1,484
2019-12-31 1,484
2019-09-30 1,483
2019-06-30 1,484
2019-03-31 1,483
2018-12-31 1,546
2018-09-30 1,515
2018-06-30 1,572
2018-03-31 1,596
2017-12-31 1,603
2017-09-30 1,603
2017-06-30 1,600
2017-03-31 1,603
2016-12-31 1,631
2016-09-30 1,640
2016-06-30 1,632
2016-03-31 1,625
2015-12-31 1,637
2015-09-30 1,664
2015-06-30 1,633
2015-03-31 1,608
2014-12-31 1,610
2014-09-30 1,610
2014-06-30 1,608
2014-03-31 1,609
2013-12-31 1,604
2013-09-30 1,605
2013-06-30 1,609
2013-03-31 1,605
2012-12-31 1,577
2012-09-30 1,577
2012-06-30 1,577
2012-03-31 1,577
2011-12-31 1,585
2011-09-30 1,300
2011-06-30 1,571
2011-03-31
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $293.876B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01